CClinicalTrials.gg
CompletedNCT02763904Updated Nov 18, 2024

Systematic Oral Nutritional Support in Hospitalized, Moderately Hypophagic Patients At Nutritional Risk

An interventional study of Intensive nutritional counseling and Dietary counseling in Nutritional Support, sponsored by Emanuele Cereda. Completed at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Emanuele Cereda · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Protein-calorie malnutrition is a frequent comorbidity in hospitalized patients and there is evidence that the nutritional status may influence the response to drug treatment, mortality, susceptibility to infections, the patient's functional status, duration of hospital stay and, consequently, overall healthcare costs. The causes of malnutrition are manifold. The underlying disease may in fact lead to an increase in the patient's energy needs, whether or not associated with a reduction in caloric intake. The same therapeutic treatments can further worsen the energy balance without considering that the patient can be kept fasting for the execution of some diagnostic procedures. Therefore, a further deterioration of nutritional status during hospitalization could occur.

International guidelines underline the utility to set a nutritional support whenever this is necessary, not only to prevent or treat malnutrition but also improve clinical outcomes. In this perspective, the improvement of oral diet and the use of oral nutritional supplements (ONS) represent the first-line strategy of intervention. Previous studies have shown that nutritional counseling, with or without the use of ONS, in patients with chronic disease is able to improve the calorie-protein intake, prevent deterioration of nutritional status, as well as to increase to a certain extent body weight. Particularly, energy-dense are more effective in increase energy intake. These data have highlighted the importance of a proper evaluation of the nutritional status of early detection of patients who could benefit of nutritional support. However, the independent role of the ONS in improving clinical outcome still needs to be established.

02

Conditions studied

  • Nutritional Support
03

In context

Lead sponsor

Emanuele Cereda is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Nutritional Risk Score [NRS-2002] ≥3
  • assessed within 48 hours since admission
  • expected length of stay ≥7 days
  • written informed consent

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years
  • ongoing or indication to artificial nutrition
  • severe hypophagia (intake \<50% of estimated requirements)
  • scheduled for surgery
  • indication to fasting
  • physician-based contra-indication to use of liquid oral nutritional supplements (vomitus, severe nausea, diarrhea, dysphagia)
  • physician-based indication to the of disease-specific oral nutritional supplements (e.g. kidney failure or pressure ulcers)
  • terminal illness
  • unavailability to planned measurements
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Intensive nutritional counseling

    Dietary counseling + energy dense oral nutritional supplements

    Dietary Supplement: Intensive nutritional counseling

  • Active comparator
    Dietary counseling

    Dietary counseling

    Other: Dietary counseling

Interventions

  • Dietary supplementIntensive nutritional counseling

    Dietary counseling + energy-dense oral nutritional supplements since admission

  • OtherDietary counseling

    Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)

06

What researchers measure

Primary outcomes

  1. Body composition

    Change in phase angle as assessed by vectorial impedance analysis

    Time frame: 7 days

Secondary outcomes

  1. Body composition

    Change in phase angle as assessed by vectorial impedance analysis

    Time frame: 14 days

  2. Body composition

    Change in phase angle as assessed by vectorial impedance analysis

    Time frame: Hospital stay, an average of 17 days

  3. Functional status

    Change in handgrip strength as assessed by dynamometry

    Time frame: 7 days

  4. Functional status

    Change in handgrip strength as assessed by dynamometry

    Time frame: 14 days

  5. Functional status

    Change in handgrip strength as assessed by dynamometry

    Time frame: Hospital stay, an average of 17 days

  6. Energy intake

    Protein-calorie intake as assessed by serial 24-hour dietary recall

    Time frame: 7 days

  7. Energy intake

    Protein-calorie intake as assessed by serial 24-hour dietary recall

    Time frame: 14 days

  8. Infections

    Incidence of new infections during the hospital stay

    Time frame: Hospital stay, an average of 17 days

  9. Adverse events

    Gastrointestinal intolerance events

    Time frame: Hospital stay, an average of 17 days

07

Study locations

1 site
  • Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02763904
Lead sponsor
Emanuele Cereda
Responsible party
Emanuele Cereda (Fondazione IRCCS Policlinico San Matteo di Pavia, Fondazione IRCCS Policlinico San Matteo di Pavia) — Sponsor-investigator
First posted
May 5, 2016
Start date
Jul 30, 2016
Primary completion
Jul 24, 2024
Completion
Jul 30, 2024
Last update
Nov 18, 2024

Study contacts

Emanuele Cereda, MD, PhD
principal investigator · Fondazione IRCCS Policlinico San Matteo
Riccardo Caccialanza, MD
study chair · Fondazione IRCCS Policlinico San Matteo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion